Hallucinations

Why Companies Are Betting Big On Psychedelic Drugs To Treat Mental Health Epidemic

Retrieved on: 
Wednesday, April 28, 2021
Psychoactive drugs, Drugs, Branches of biology, Entheogens, Hallucinations, Counterculture of the 1960s, Psychoactive fungi, Psychedelic drugs, Psilocybin mushroom, Psilocybin, Recreational drug use, Hallucinogen

Once dismissed as a "party drug" for its hallucinogenic effects, ketamine is emerging as a novel alternative treatment for depression.

Key Points: 
  • Once dismissed as a "party drug" for its hallucinogenic effects, ketamine is emerging as a novel alternative treatment for depression.
  • For most, psychedelic drugs conjure up images of the 1960\'s, hippies tripping out on LSD or magic mushrooms.
  • However, early studies are finding that psilocybin the active agent in magic mushrooms could treat addiction, depression, anxiety and mental health conditions like post-traumatic stress disorder (PTSD).
  • You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.

Why Companies Are Betting Big On Psychedelic Drugs To Treat Mental Health Epidemic

Retrieved on: 
Wednesday, April 28, 2021
Psychoactive drugs, Drugs, Branches of biology, Entheogens, Hallucinations, Counterculture of the 1960s, Psychoactive fungi, Psychedelic drugs, Psilocybin mushroom, Psilocybin, Recreational drug use, Hallucinogen

Once dismissed as a "party drug" for its hallucinogenic effects, ketamine is emerging as a novel alternative treatment for depression.

Key Points: 
  • Once dismissed as a "party drug" for its hallucinogenic effects, ketamine is emerging as a novel alternative treatment for depression.
  • For most, psychedelic drugs conjure up images of the 1960\'s, hippies tripping out on LSD or magic mushrooms.
  • However, early studies are finding that psilocybin the active agent in magic mushrooms could treat addiction, depression, anxiety and mental health conditions like post-traumatic stress disorder (PTSD).
  • You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.

PSYC CEO, David Flores, To Be Featured on Live Cheddar TV Segment

Retrieved on: 
Tuesday, April 27, 2021
Drug culture, Hallucinations, Psychedelic drug, Health, Harm reduction, Articles

This is based on encouraging data and information from ongoing research and studies into the therapeutic benefits of specific psychedelic compounds.\n\xe2\x80\x9cI am very excited for this wonderful opportunity to have PSYC featured on the Cheddar TV network,\xe2\x80\x9d said Flores.

Key Points: 
  • This is based on encouraging data and information from ongoing research and studies into the therapeutic benefits of specific psychedelic compounds.\n\xe2\x80\x9cI am very excited for this wonderful opportunity to have PSYC featured on the Cheddar TV network,\xe2\x80\x9d said Flores.
  • Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved.
  • We support a harm reduction approach for the purpose of education and promoting individual and public safety.
  • If you are choosing to use psychedelic substances, please do so responsibly.\n'

AIkido Pharma Announces Dr. Rachel Yehuda's Appearance at SXSW

Retrieved on: 
Tuesday, April 27, 2021
Psychiatry, Branches of biology, Mind, Abnormal psychology, Psychiatric diagnosis, Entheogens, Mental health professionals, Hallucinations, Psychedelic drug, Psilocybin, Mental health, Mental disorder

b'NEW YORK, April 27, 2021 /PRNewswire/ --AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that Dr. Rachel Yehuda appeared at SXSW for a panel discussion entitled Psychedelics: Rewiring Mental Health Care.

Key Points: 
  • b'NEW YORK, April 27, 2021 /PRNewswire/ --AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that Dr. Rachel Yehuda appeared at SXSW for a panel discussion entitled Psychedelics: Rewiring Mental Health Care.
  • The SXSW panel discussed ongoing clinical trials, recent medical discoveries, and how psilocybin may be part of the solution to our mental health crisis.
  • The session is available on demand at the SXSW website.\nAs previously noted, there are 45 million Americans with a mental illness.
  • Designated as "breakthrough therapy" by the FDA, psilocybin therapy has the potential to reinvent the paradigm for treating psychiatric disorders like addiction, PTSD and depression.

PharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics with panaceAI™

Retrieved on: 
Tuesday, April 27, 2021
Drugs, Psychoactive drugs, Hallucinations, Clinical research, Drug Safety, Food and Drug Administration, Investigational New Drug, Psychedelic drug, Ketamine

The Company has submitted an Investigational New Drug (\xe2\x80\x9cIND\xe2\x80\x9d) application with the U.S. Food and Drug Administration (\xe2\x80\x9cFDA\xe2\x80\x9d) for the initiation of a Phase 2 clinical trial to evaluate ketamine in the treatment of Parkinson\xe2\x80\x99s disease.

Key Points: 
  • The Company has submitted an Investigational New Drug (\xe2\x80\x9cIND\xe2\x80\x9d) application with the U.S. Food and Drug Administration (\xe2\x80\x9cFDA\xe2\x80\x9d) for the initiation of a Phase 2 clinical trial to evaluate ketamine in the treatment of Parkinson\xe2\x80\x99s disease.
  • Upon the FDA accepting the IND, PharmaTher will leverage the IND to expand the clinical development of ketamine in depression, amyotrophic lateral sclerosis (Lou Gehrig\xe2\x80\x99s disease), pain and obesity-related disorders.\nPharmaTher uses its drug repurposing AI platform, panaceAI\xe2\x84\xa2, to expand on the Company\xe2\x80\x99s patent portfolio of novel uses of DMT, MDMA and LSD.
  • PharmaTher\xe2\x80\x99s objective is to discover novel uses of these psychedelics and incorporate them into the Company\xe2\x80\x99s proprietary microneedle patch delivery system currently being evaluated at the Terasaki Institute.
  • The Company seeks to commercialize the product developments either internally or partner with life sciences companies seeking to expand their product portfolio with psychedelics.

Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003

Retrieved on: 
Monday, April 26, 2021
Alternative medicine, Mental health, Health, General Health, Pharmaceutical, Biotechnology, Hallucinations, Entheogens, Psychoactive drugs, Psychedelic drug, Psychoactive fungi, Hallucinogen, Psilocybin, Branches of biology, Symptoms and signs

The severity of AUD\xe2\x80\x94mild, moderate, or severe\xe2\x80\x94is based on the number of criteria met.1\n"The evidence of increased alcohol use during this ongoing pandemic is startling.

Key Points: 
  • The severity of AUD\xe2\x80\x94mild, moderate, or severe\xe2\x80\x94is based on the number of criteria met.1\n"The evidence of increased alcohol use during this ongoing pandemic is startling.
  • For so many individuals and families, Alcohol Use Disorder can be disruptive, even devastating.
  • There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition.
  • Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials.

REPEAT: Core One Labs’ Vocan Initiates Engineering and Design of a Proprietary Production System for Manufacturing of API-Grade DMT

Retrieved on: 
Wednesday, April 21, 2021
Entheogens, Psychoactive drugs, Hallucinations, Amines, Mycotoxins, Branches of biology, Ayahuasca, Psychedelic drugs, N,N-Dimethyltryptamine, Psilocybin, Hallucinogen, DMT

With further development the research team plans to construct a high-throughput production system based on the same recombinant enzyme fermentation platform the company is already developing for API-psilocybin.

Key Points: 
  • With further development the research team plans to construct a high-throughput production system based on the same recombinant enzyme fermentation platform the company is already developing for API-psilocybin.
  • The team intends to accelerate the current development stage of its DMT production system within a few weeks in order to fast-track the first DMT provisional patent filling with the US Patent and Trademark Office.
  • The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin.
  • Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients.

The Power of the Platform in Psychedelic Medicine

Retrieved on: 
Tuesday, April 20, 2021
Drugs, Psychoactive drugs, Health sciences, Hallucinations, Euphoriants, Ketamine, Sedatives, Digital medicine, Medication, Psychedelic drug

OTC Stock Review introduced a large number of investors to the psychedelic sector with an article on Seeking Alpha March 6, 2020 titled " Psychedelic Medicine Stocks Capture the Attention of Investors ."

Key Points: 
  • OTC Stock Review introduced a large number of investors to the psychedelic sector with an article on Seeking Alpha March 6, 2020 titled " Psychedelic Medicine Stocks Capture the Attention of Investors ."
  • MindMed recently announced it would establish a digital medicine division known as Albert to research, develop and build an integrated technical platform and comprehensive toolset aimed at delivering psychedelic inspired medicines and experiential therapies combined with digital therapeutics.
  • It is a data driven platform that has been strategically developed to provide better communication among medical practitioners and health care providers.
  • Ehave\'s Dashboard is also a key component of its ketamine home delivery platform known as KetaDASH www.ketadash.com.

Psychedelic Experience launches new website to help navigate the world of psychedelics

Retrieved on: 
Thursday, April 22, 2021
Drug culture, Spirituality, Human behavior, Entheogens, Underground culture, Video games, Hallucinations, Psychedelia, Psychedelic drug, Psychonauts, Psychonautics, Cross-linked polyethylene

Want to find a psilocybin retreat in the Netherlands, or an Integration Therapist in the U.S. or U.K.?PEx\'s Directory has it.

Key Points: 
  • Want to find a psilocybin retreat in the Netherlands, or an Integration Therapist in the U.S. or U.K.?PEx\'s Directory has it.
  • New to psychedelics and not ready for a full-on experience?
  • No problem!\nPEx\'s website is designed to cater to your needs, with content options for beginners, those with some experience, and those that consider themselves to be more experienced psychonauts.
  • We are a passionate team, driven by the belief that entheogens can change the world for the better.

Psychedelic Drugs Market Size Is Projected To Reach $10.75 Billion By 2027

Retrieved on: 
Wednesday, April 21, 2021
Psychoactive drugs, Hallucinations, Drugs, Branches of biology, Hallucinogen, Dissociative drugs, Euphoriants, Stimulants, Dissociative, Psychedelic drug, Lysergic acid diethylamide, Empathogen–entactogen

A recent report from Data Bridge Market Research said that the psychedelic drugs market is expected to gain market growth in the forecast period of 2020 to 2027.

Key Points: 
  • A recent report from Data Bridge Market Research said that the psychedelic drugs market is expected to gain market growth in the forecast period of 2020 to 2027.
  • Another report from Research And Markets upped the projection saying that the Psychedelic Drugs Market size is projected to reach USD $10.75 Billion by 2027, from USD 4.75 Bn in 2020 growing at a CAGR of 12.36% during 2021-2027.
  • Psychedelic drugs can be categorized into dissociative drugs (such as PCP), empathogens and serotonergic (classic hallucinogens) (such as LSD).
  • Psychedelic drugs market has increased with increased number of psychedelic drugs as compared to the past few years and increasing prevalence of depression and mental disorders in the U.S.